Literature DB >> 1981623

Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects.

M L Rao1, G Gross, B Strebel, P Bräunig, G Huber, J Klosterkötter.   

Abstract

Basal serum amino acids (including central monoamine precursors), central monoamines, and hormones were studied in schizophrenic patients (drug-naive; n = 20; drug-withdrawn for 3 or more days, n = 67; neuroleptic-treated, n = 23) and healthy subjects (n = 90) to answer the following questions: (1) Do neuroleptic-withdrawn and neuroleptic-naive patients differ on these serum measures? (2) What are the effects of neuroleptic treatment on these measures? (3) On which variables do drug-free and neuroleptic-treated patients differ? Because serum amino acid, central monoamine, and hormone levels were similar in drug-naive and drug-withdrawn patients, data from these groups ("drug-free") were combined and compared to those of healthy subjects and neuroleptic-treated patients. Asparagine, citrulline, phenylalanine, and cysteine were higher, while tyrosine, tryptophan, and the ratio of tryptophan to competing amino acids were significantly lower in drug-free schizophrenic patients than in healthy subjects. Dopamine was increased, and melatonin and thyroid hormones were decreased in drug-free schizophrenic patients compared to healthy subjects. Norepinephrine, epinephrine, and prolactin were higher in neuroleptic-treated men compared to drug-free male patients or healthy men. These results are consistent with the hypothesis of dopaminergic overactivity in schizophrenia, which might be caused by altered amino acid precursor availability and could be related to the decrease in melatonin and reduction in thyroid hormone levels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981623     DOI: 10.1016/0165-1781(90)90003-n

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  21 in total

1.  Reciprocal moderation by Toxoplasma gondii seropositivity and blood phenylalanine - tyrosine ratio of their associations with trait aggression.

Authors:  Ashwin Jacob Mathai; Christopher A Lowry; Thomas B Cook; Lisa A Brenner; Lena Brundin; Maureen W Groer; Xiaoqing Peng; Ina Giegling; Annette M Hartmann; Bettina Konte; Marion Friedl; Dietmar Fuchs; Dan Rujescu; Teodor T Postolache
Journal:  Pteridines       Date:  2016-10-21       Impact factor: 0.581

2.  Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcome.

Authors:  Catherine L Clelland; Laura L Read; Amanda N Baraldi; Corinne P Bart; Carrie A Pappas; Laura J Panek; Robert H Nadrich; James D Clelland
Journal:  Schizophr Res       Date:  2011-06-08       Impact factor: 4.939

3.  Vitamin D insufficiency and schizophrenia risk: evaluation of hyperprolinemia as a mediator of association.

Authors:  James D Clelland; Laura L Read; Valérie Drouet; Angela Kaon; Alexandra Kelly; Karen E Duff; Robert H Nadrich; Amit Rajparia; Catherine L Clelland
Journal:  Schizophr Res       Date:  2014-04-29       Impact factor: 4.939

4.  Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia.

Authors:  Cigdem Sahbaz; Omer Faruk Özer; Ayse Kurtulmus; Ismet Kırpınar; Fikrettin Sahin; Sinan Guloksuz
Journal:  Metab Brain Dis       Date:  2019-02-13       Impact factor: 3.584

Review 5.  Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting.

Authors:  N Zisapel
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

6.  The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments.

Authors:  Abbas F Almulla; Asara Vasupanrajit; Chavit Tunvirachaisakul; Hussein K Al-Hakeim; Marco Solmi; Robert Verkerk; Michael Maes
Journal:  Mol Psychiatry       Date:  2022-04-14       Impact factor: 15.992

7.  Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects.

Authors:  Stefan Cohrs; Kathrin Pohlmann; Zhenghua Guan; Wolfgang Jordan; Andreas Meier; Gerald Huether; Eckart Rüther; Andrea Rodenbeck
Journal:  Psychopharmacology (Berl)       Date:  2004-01-20       Impact factor: 4.530

8.  Tryptophan Metabolism and White Matter Integrity in Schizophrenia.

Authors:  Joshua Chiappelli; Teodor T Postolache; Peter Kochunov; Laura M Rowland; S Andrea Wijtenburg; Dinesh K Shukla; Malle Tagamets; Xiaoming Du; Anya Savransky; Christopher A Lowry; Adem Can; Dietmar Fuchs; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2016-05-04       Impact factor: 7.853

9.  Peripheral amino Acid levels in schizophrenia and antipsychotic treatment.

Authors:  Vincenzo De Luca; Emanuela Viggiano; Giovanni Messina; Alessandro Viggiano; Carol Borlido; Andrea Viggiano; Marcellino Monda
Journal:  Psychiatry Investig       Date:  2008-12-31       Impact factor: 2.505

10.  Are cardiometabolic and endocrine abnormalities linked to sleep difficulties in schizophrenia? A hypothesis driven review.

Authors:  Rébecca Robillard; Naomi L Rogers; Bradley G Whitwell; Tim Lambert
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-04-30       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.